Dapagliflozin Tested in Anemic Adults With Chronic Kidney Disease
Tests dapagliflozin with anemia treatment in adults with chronic kidney disease.
Key facts
- Who runs it
- Mansoura University
- Where
- Al Mansurah, EgyptSee the site
- Trial code
- Registry title
- Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 80 people, planned
- Started
- 1 Apr 2025
- Planned end
- Oct 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- Dapagliflozin (DAPA)
- Erythropoiesis Stimulating Agent
- Record updated
- 2 April 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage III or IV chronic kidney disease and anemia who already receive erythropoiesis-stimulating agent therapy.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Chronic kidney disease stage III or IV, with anemia caused by the kidney disease.
- Earlier treatment
- People must be receiving erythropoiesis-stimulating agent therapy.
- Biomarker or test result
- Hemoglobin level below 11.5 g/dL.
Main reasons for not taking part
- Anemia from other causes, such as pernicious anemia, thalassemia, sickle cell anemia or myelodysplastic syndromes
- Acute heart failure, acute myocardial infarction or stroke within 6 months before enrollment
- Current cancer, or cancer within the past 2 years
- Pure red cell aplasia or severe gastrointestinal bleeding
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Adults aged ≥ 18 years with CKD stage III or IV
- Patients with anemia of CKD and a hemoglobin level < 11.5 g/dL
- Patients are receiving erythropoiesis-stimulating agent therapy
Who cannot take part
- Patients with acute heart failure, acute myocardial infarction, or stroke occurring within 6 months before enrollment in the trial
- Anemia due to causes other than chronic kidney disease, such as pernicious anemia, thalassemia, sickle cell anemia, or myelodysplastic syndromes
- Patients with severe ketosis, diabetic coma, severe infection, perioperative complications, or severe trauma
- Patients with current malignancies or a history of malignancy within the past 2 years
- Patients with severe gastrointestinal bleeding
- Diagnosed with pure red cell aplasia
- Pregnant or lactating females
Where in Egypt
- Urology and Nephrology CenterAl Mansurah, EgyptContact: Basma M. Sayed Ahmed, M.Sc.Taking people
About the trial
What the trial wants to find out
Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, primarily used in the management of type 2 diabetes mellitus. Emerging research suggests that SGLT2 inhibitors may offer additional benefits, including reducing the risk of cardiovascular events and renal complications. Post hoc analyses of previous clinical trials have shown that patients treated with SGLT2 inhibitors exhibited higher levels of hemoglobin and hematocrit compared to those in the control group. These findings suggest that dapagliflozin's ability to elevate hemoglobin levels could potentially be utilized for the treatment of anemia in patients with chronic kidney disease.
The 2 groups in the trial
- Dapagliflozin + ESA groupTreatment being tested
patients will receive dapagliflozin 10 mg tablet once daily in addition to standard care therapy of erythropoiesis-stimulating agents (ESA)
Treatment: Dapagliflozin (DAPA) and Erythropoiesis Stimulating Agent
- Control groupOther group
patients will receive standard care therapy of erythropoiesis-stimulating agents (ESA)
Treatment: Erythropoiesis Stimulating Agent
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Clinical Study Evaluating the Impact of Dapagliflozin on Erythropoiesis-Stimulating Agent Responsiveness in Anemic Patients With Chronic Kidney Disease
- Plain-language title
- Dapagliflozin Tested in Anemic Adults With Chronic Kidney DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 April 2025